Johnson & Johnson to Acquire Austin Biotech Ollin Biosciences in Deal Worth Up to $3.3 Billion

M
mfornes
Nov 17, 2026 Austin

J&J Signs Up to $3.3 Billion Definitive Agreement for Austin's Ollin Biosciences

AUSTIN, Texas — Healthcare giant Johnson & Johnson announced a definitive agreement to acquire Austin-based clinical-stage biotechnology firm Ollin Biosciences in a transaction valued at up to $3.3 billion, including $2.2 billion paid upfront. Ollin focuses on developing therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

SunHydrogen Shares Outdoor Solar-to-Hydrogen Pilot Update at UT Austin

In clean-energy technology news, SunHydrogen released a milestone video update highlighting outdoor testing of its full-size solar-to-hydrogen panels at its pilot site at the University of Texas at Austin as the technology advances toward commercial deployment.

UT Austin Study in PLOS Biology Explains How the Brain Filters Speech From Noise

Separately, University of Texas at Austin researchers published new findings in PLOS Biology showing how the human brain effortlessly learns to amplify meaningful sounds such as speech and familiar voices over background noise, offering fresh insight into communication disorders.